|
|
Argos Therapeutics' Arcelis™ Immunotherapy for Renal Cell Carcinoma ... - Sacramento Bee |
|
Sacramento BeeBy Argos Therapeutics CHICAGO, Oct. 1 -- /PRNewswire/ -- Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), ...Argos Therapeutics' Arcelis(TM) Immunotherapy for Renal Cell Carcinoma ... |
|
|
Argos Therapeutics' Arcelis(TM) Immunotherapy for Renal Cell Carcinoma ... - SYS-CON Media (press release) |
|
SYS-CON Media (press release)CHICAGO, Oct. 1 /PRNewswire/ -- Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable ...Argos Therapeutics' Arcelis™ Immunotherapy for Renal Cell Carcinoma ... |
|
KAI Pharma initiates phase 1b study of KAI-4169 for secondary ... - pharmabiz.com |
|
pharmabiz.comMineral and bone disorders can be devastating to the health of ESRD patients with SHPT. KAI is committed to addressing this compelling medical need. ... |
|
DaVita To Sell $1.45B Of Notes To Fund Debt-Refinance Plan - Wall Street Journal |
|
Wall Street JournalDaVita Inc. (DVA) plans to sell $1.45 billion of notes to fund the potential repurchase of up to $1.55 billion of debt as the operator of dialysis centers ...DaVita offering $1.45 billion in senior notes CanadianBusiness.comDaVita Inc. Commences Cash Tender Offers and Consent Solicitations for Any and ... |
|
NKTI urges public to enroll in PhilHealth - Philippine Information Agency |
|
Philippine Information AgencyMembership to PhilHealth, according to NKTI Adult Nephrology Department chair Dr. Romina Danguilan, reduces hospital and treatment bills. ... |
|
|
|
|
<< Start < Prev 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 Next > End >>
|
|
Page 1287 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
